Market risk analysis of Chinese antilipidemic drugs

is a general term for the cholesterol, triglycerides (TG) and lipids (such as phospholipids) in the serumHyperlipidemia is a common diseaseClinically, dyslipidemia includes low density lipoprotein cholesterol (LDL-C), high density lipoprotein cholesterol (HDL-C) and / or TG levels, and the incidence rate is high among the middle aged and elderly peopleIt can directly cause some serious diseases that endanger human health, such as atherosclerosis, coronary heart disease, pancreatitis and so on< br / > the guideline for the prevention and treatment of Chinese adult dyslipidemia (2016 Revision) points out that the overall prevalence rate of Chinese adult dyslipidemia is as high as 40.40%, and the increase of serum cholesterol level will lead to an increase of 9.2 million cardiovascular events in China during 2010-2030The level of blood lipid in Chinese population gradually increased, and the prevalence of dyslipidemia increased significantlyThe results of the national survey in 2012 showed that the prevalence of hypercholesterolemia was 4.9%; the prevalence of hypertriglyceridemia (TG) was 13.1%; and the prevalence of LDL-C was 33.9%< br / > the dyslipidemia characterized by the increase of LDL-C or TC is an important risk factor for atherosclerotic cardiovascular disease (ASCVD)The decrease of LDL-C can significantly reduce the risk of ASCVDAt present, there are many antilipidemic drugs, which can be roughly divided into five categories according to different mechanisms of action: clofibrate and phenoxyacetic acid, trimethylolglutaryl coenzyme A reductase inhibitors, niacin and its derivatives, cholic acid integrators and other drugs (Figure 1)< br / > Chart 1: classification of antilipidemic drugs < br / > < br / > at present, trimethylolglutaryl coenzyme A reductase inhibitors are characterized by good selectivity, high efficacy and few side effectsThey are the leading drugs for the treatment of hypercholesterolemiaIn 2018, atorvastatin accounted for 48.7% of the domestic antilipidemic drugs, followed by rosuvastatin, accounting for 25.1%; pivastatin calcium, pravastatin and simvastatin accounted for less than 6%, others accounted for 12.7%The third-generation statins of atorvastatin, rosuvastatin and pivastatin are superior to the previous two generations in terms of lipid-lowering effect and drug safetyIn addition, due to the expiration of the original research patent, the market share will continue to increase for some time in the futureSince the advent of lovastatin in 1987, statins have rapidly become the first choice in clinical treatmentAt present, the latest generation of statins are atorvastatin, rosuvastatin and pivastatin, which were approved by FDA in 1996, 2003 and 2009, respectivelyWith regard to lipid-lowering effect and drug safety, statins are still the most effective drugs to reduce the mortality of cardiovascular and cerebrovascular diseases so far, and few new lipid-lowering drugs have been developed and marketed in the world< br / > 2Chinese local brands are lack of competitiveness < br / > Chinese local enterprises mainly produce generic drugs, with many enterprises and fierce competitionFor example, when the patent period of atorvastatin expired in 2011, according to the data of National Drug Administration (nmpa), the generic drugs of atorvastatin, including Hengrui group, Shiyao group, Haizheng pharmaceutical, Qilu pharmaceutical and other pharmaceutical companies, have been listed in succession; at present, the generic drugs of rosuvastatin are also produced by many pharmaceutical companies, including Jingxin pharmaceutical, Zhengda Tianqing pharmaceutical, Haizheng pharmaceutical and so on< br / > 3Centralized purchase of national drugs < br / > since the implementation of centralized purchase of national drugs, the mechanism of price for quantity is effective, the downward pressure on product price will gradually increase, and the possibility of price reduction in centralized purchase of national drugs will greatly increase for the former research and drug enterprises to consolidate the market< br / > 4The strong intervention of health products < br / > the common saying "it's the third poison of medicine" is deeply rooted in people's hearts, which makes the public, especially the middle-aged and old people, prefer to buy health products rather than drugs, such as fish oil soft capsule, soybean lecithin capsule, natto Hongqu capsule and natto Ginkgo biloba extract capsule, which have the function of auxiliary lowering blood lipid.